MS
PTCT icon

Maven Securities’s PTC Therapeutics PTCT Stock Holding History

Maven Securities’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-46,058
Closed -$2.17M – 1277
2021
Q1 		$2.17M Buy
46,058
+34,058
+284% +$2.02M 0.1% 203
2020
Q4 		$739K Buy
+12,000
New +$707K 0.07% 290
2018
Q2 		– Sell
-34,860
Closed -$943K – 93
2018
Q1 		$943K Buy
+34,860
New +$883K 0.5% 34

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Maven Securities's PTCT Position: Q2 2021 in Review

Maven Securities sold out of PTC Therapeutics (PTCT) in Q2 2021, closing a stake of 46,058 shares — an estimated $2.17M sold.

Maven Securities first reported a position in PTCT in Q1 2018 and held it in 3 quarters. The position peaked at $2.17M in Q1 2021. 182 funds tracked by Wall St. Rank hold PTCT as of Q2 2021.

  • Maven Securities reported no remaining PTC Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Maven Securities sold 46,058 PTC Therapeutics shares in Q2 2021, an estimated $2.17M.
  • Maven Securities first reported a position in PTC Therapeutics in Q1 2018 and held it in 3 quarters.
  • Maven Securities's PTC Therapeutics position peaked at $2.17M in Q1 2021.
  • 182 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.